Generic Portal

— Research Explorer

Case report: Pharmacokinetics of pembrolizumab in a patient with stage IV non?small cell lung cancer after a single 200 mg administration

Research output: Contribution to journal › Article › Academic › peer-review

immune-related adverse events, immunotherapy, pembrolizumab, pharmacodynamic (PD), pharmacokinetic (PK), programmed cell death protein 1 (PD-1)

ID: 32162805